These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28344893)

  • 1. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.
    Kiyotani K; Park JH; Inoue H; Husain A; Olugbile S; Zewde M; Nakamura Y; Vigneswaran WT
    Oncoimmunology; 2017; 6(2):e1278330. PubMed ID: 28344893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers.
    Kato T; Park JH; Kiyotani K; Ikeda Y; Miyoshi Y; Nakamura Y
    Oncotarget; 2017 Sep; 8(37):62029-62038. PubMed ID: 28977923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
    de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
    J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns.
    Li Z; Chen G; Cai Z; Dong X; He L; Qiu L; Zeng Y; Liu X; Liu J
    Chin J Cancer Res; 2021 Jun; 33(3):364-378. PubMed ID: 34321833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.
    Chen R; Lee WC; Fujimoto J; Li J; Hu X; Mehran R; Rice D; Swisher SG; Sepesi B; Tran HT; Chow CW; Little LD; Gumbs C; Haymaker C; Heymach JV; Wistuba II; Lee JJ; Futreal PA; Zhang J; Reuben A; Tsao AS; Zhang J
    Clin Cancer Res; 2020 Oct; 26(20):5477-5486. PubMed ID: 32816946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.
    Cedres S; Serna G; Gonzalez-Medina A; Valdivia A; Assaf-Pastrana JD; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Priano I; Fasani R; Guardia X; Gonzalo J; Carbonell C; Frigola J; Amat R; Navarro V; Dienstmann R; Vivancos A; Nuciforo P; Felip E
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
    Tolani B; Acevedo LA; Hoang NT; He B
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
    Salaroglio IC; Kopecka J; Napoli F; Pradotto M; Maletta F; Costardi L; Gagliasso M; Milosevic V; Ananthanarayanan P; Bironzo P; Tabbò F; Cartia CF; Passone E; Comunanza V; Ardissone F; Ruffini E; Bussolino F; Righi L; Novello S; Di Maio M; Papotti M; Scagliotti GV; Riganti C
    J Thorac Oncol; 2019 Aug; 14(8):1458-1471. PubMed ID: 31078776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review.
    Désage AL; Karpathiou G; Peoc'h M; Froudarakis ME
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer.
    Choudhury NJ; Kiyotani K; Yap KL; Campanile A; Antic T; Yew PY; Steinberg G; Park JH; Nakamura Y; O'Donnell PH
    Eur Urol Focus; 2016 Oct; 2(4):445-452. PubMed ID: 28723478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
    Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.
    Meiller C; Montagne F; Hirsch TZ; Caruso S; de Wolf J; Bayard Q; Assié JB; Meunier L; Blum Y; Quetel L; Gibault L; Pintilie E; Badoual C; Humez S; Galateau-Sallé F; Copin MC; Letouzé E; Scherpereel A; Zucman-Rossi J; Le Pimpec-Barthes F; Jaurand MC; Jean D
    Genome Med; 2021 Jul; 13(1):113. PubMed ID: 34261524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell receptor β-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma.
    Lu Z; Zhang C; Sheng J; Shen J; Liu B
    Int J Cancer; 2017 Jul; 141(2):377-382. PubMed ID: 28431188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
    Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.